as Vice President, Clinical Operations. Ms. Andor will lead the Company’s expanding Clinical Operations function in support of the ongoing Phase 3 program evaluating oral levosimendan (TNX-103 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback